Aims In end-stage heart failure, an alteration in the expression of the Na + -Ca 2+ exchanger has been reported. Regulation of its expression is largely unknown. We sought to find out whether Na + -Ca 2+ exchanger in human heart failure is regulated by sympathetic activation. In addition, since Na + -Ca 2+ -exchange is electrogenic, we conjectured whether increased expression of Na + -Ca 2+ exchanger is associated with an increased incidence of cardiac arrhythmias.
Aims In end-stage heart failure, an alteration in the expression of the Na + -Ca 2+ exchanger has been reported. Regulation of its expression is largely unknown. We sought to find out whether Na + -Ca 2+ exchanger in human heart failure is regulated by sympathetic activation. In addition, since Na + -Ca 2+ -exchange is electrogenic, we conjectured whether increased expression of Na + -Ca 2+ exchanger is associated with an increased incidence of cardiac arrhythmias.
Methods and Results
Twenty-three patients suffering from end-stage cardiac failure were examined in the hours preceding cardiac transplantation. Plasma levels of norepinephrine, epinephrine, atrial natriuretic peptide, renin activity, aldosterone, tumour necrosis factor (TNF)-, and TNF-receptors were measured. All parameters were elevated relative to 21 healthy control subjects. As determined by immunoblots, protein levels of the Na + -Ca 2+ exchanger were increased by 56% and protein levels of sarcoplasmic reticulum (SR) Ca 2+ -ATPase were decreased by 20% in left ventricles of the explanted failing hearts. A significant correlation between protein and neurohumoral levels was exclusively found for the Na + -Ca 2+ exchanger with norepinephrine (r=0·64; P=0·01). Recent Holter ECGs revealed that patients with sustained or nonsustained ventricular tachycardia (more than three consecutive beats) had significantly higher Na + -Ca 2+ exchanger protein and plasma norepinephrine levels than patients with a maximum of two consecutive beats (Na + -Ca 2+ exchanger: 109 10 vs 83 7, n=11 each, P<0·05; norepinephrine: 1359 159 vs 656 88 pg . ml 1 , n=9 each, P<0·001).
Introduction
Alterations in excitation-contraction coupling may play a crucial role in the impairment of myocardial performance in human heart failure. The underlying mechanisms involve disturbed regulation of systolic and diastolic calcium transients due to decreased sarcoplasmic reticulum (SR) calcium uptake. This in turn may result from the altered expression and function of SR-Ca 2+ -ATPase and the sarcolemmal Na + -Ca 2+ -exchanger [1, for review] . However, the role of the Na + -Ca 2+ exchanger in human heart failure and hypertrophy is incompletely understood. Initial studies in human myocardium from transplant recipients reported increased expression and function in end-stage heart failure [2] [3] [4] . Other studies found that Na + -Ca 2+ -exchanger expression was unaltered at the protein level [5] and similarly, transcript levels in myocardial biopsies from patients with various degrees of ventricular dysfunction were also unchanged [6] . Recent data from our group suggested that two distinct phenotypes may exist: (1) hearts with decreased SR-Ca 2+ -ATPase and unchanged Na + -Ca 2+ -exchanger expression exhibiting severe systolic and diastolic dysfunction and (2) hearts with unchanged SR-Ca 2+ -ATPase and increased Na + -Ca 2+ -exchanger expression exhibiting impaired systolic but preserved diastolic function. The latter was suggested to result from increased trans-sarcolemmal Ca 2+ elimination by forward-mode Na + -Ca 2+ exchange and SR Ca 2+ depletion [7] . Regulation of the expression of Ca 2+ regulatory proteins in heart failure is largely unknown. Since chronic heart failure is a complex syndrome which, apart from myocardial alterations and increased wall stress, is characterized by abnormalities of haemodynamic, renal, neural, and hormonal factors, altered myocardial gene expression could derive from a variety of multiple factors [8] [9] [10] . Therefore, insight into the gene control of Ca 2+ cycling proteins in heart failure could be helpful in understanding the functional impact of these proteins in cardiac disease. Previously, a gradient in SR Ca 2+ -ATPase protein and mRNA was found across the left ventricular wall of human hearts, decreasing from the subepicardial to the subendocardial layers, whereas no significant gradient was observed for the Na + -Ca 2+ -exchanger [11] . Because wall stress is highest in the subendocardial layer, it was hypothesized that wall stress could be a major regulatory mechanism in SR-Ca 2+ -ATPase gene expression, while Na + -Ca 2+ -exchanger expression may be independent from wall stress. Recent studies demonstrated the dependence of Na + -Ca 2+ -exchanger expression by chronic -and -adrenergic stimulation in cultured rat cardiac myocytes [12, 13] . Also, in vivo studies performed by Golden and co-workers established the influence of catecholamines on the protein abundance of the Na + -Ca 2+ -exchanger in rat myocardium [14] . Accordingly, we hypothesized that in the human heart Na + -Ca 2+ -exchanger gene expression could be regulated by sympathetic activation. Because the Na + -Ca 2+ -exchanger catalyzes the countertransport of three Na + ions for one Ca 2+ ion across the sarcolemma [15] and therefore is electrogenic, increased expression of the Na + -Ca 2+ -exchanger could be associated with increased ventricular arrhythmias. In order to investigate these hypotheses, we measured Ca 2+ -cycling proteins in the explanted failing hearts of transplant recipients as well as plasma catecholamines prior to transplantion. These data were compared to findings in recent Holter ECGs. In addition, we measured the activity of the renin-angiotensin system and plasma levels of cytokines, as well as haemodynamics, prior to transplantation to characterize the severity of heart failure. Data from healthy subjects were gathered for comparison.
Methods

Patients
Twenty-three patients suffering from end-stage heart failure due to dilated (n=6) or ischaemic cardiomyopathy (n=17) were examined in the hours before cardiac transplantation. All patients gave informed consent. Previous drug treatment included diuretics (n=23), ACE-inhibitors (n=22), digitalis (n=18), beta-blockers (n=2), antiarrhythmics (n=8), and nitrates (n=19). None of the patients received catecholamines prior to transplantation. Echocardiography (Table 1 ) was per- Data from healthy subjects derive from our recent publication [16] . ***P<0·0001, **P<0·001, *P<0·05, ns P<0·0566.
Expression of Na + -Ca 2+ -exchanger in human heart failure 1119 formed within 3 months prior to cardiac transplantation. Haemodynamic data (Table 1) were obtained with a Swan-Ganz catheter placed in the pulmonary artery a few hours (n=16) or within 6 months (n=7) before cardiac transplantation. Patients were assigned to 'high grade' or 'low grade' arrhythmia groups, according to the findings in Holter ECGs performed within 3 (n=13) or 12 (n=9) months (Table 2) . Non-failing myocardium was obtained from 10 brain dead organ donors who were withdrawn from transplantation for technical reasons. Neurohumoral data from 21 healthy subjects from a recently published work were taken for comparison [16] . The study was approved by the Ethical Committee of the University Clinics of Goettingen and the procedures followed were in accordance with institutional guidelines.
Na + -Ca 2+ -exchanger and SR-Ca 2+ -ATPase protein levels
After cardiectomy, specimens from the left ventricular free wall of the failing hearts were excised, quickly frozen in liquid nitrogen and stored at 80 . Semiquantitative analyses of myocardial protein levels were performed by Western immunoblot as described in detail elsewhere [7] . Na + -Ca 2+ -exchanger and SR-Ca 2+ -ATPase protein levels were normalized to calsequestrin.
Plasma levels of neurohormones
Venous blood samples were taken from 19 patients (within 6 h before cardiac transplantation) and 21 healthy subjects after 30 min of supine rest, centrifuged within 1 h and stored at 80 C until use. Hormone assays were performed using previously described methods and commercially available test kits. Plasma norepinephrine and epinephrine were measured by highperformance liquid chromatography [18, 19] , (sensitivity 10 pg ml 1 ). Renin activity (REN-CTK, Sorin Biomedica, sensitivity 0·2 ng ml 1 ), atrial natriuretic peptide (ANP 125 I RIA Kit, Incstar, sensitivity 7 pg ml 1 ), and aldosterone (Aldosterone RIA CT, Radim, sensitivity 8·8 pg ml 1 ) were measured by radioimmunoassay. Antigenic TNF-(TNF-Elisa Kit, Biosource, sensitivity 3 pg ml 1 ), serum sTNF-R1 (Human sTNFRI Quantikine R&D Systems, sensitivity 3 pg ml 1 ) and sTNF-R2 levels (Human sTNFRII Quantikine R&D Systems, sensitivity 1 pg ml 1 ) were assessed by ELISA.
Data analyses and interpretation
Data are expressed as mean SEM. For technical reasons, protein and neurohumoral measurements or Holter ECGs could not be obtained from all patients. Thus, data points presenting protein or neurohumoral levels in one figure may be missing in another. Differences between myocardial protein levels and neurohumoral parameters were tested for significance by unpaired t-test or by ANOVA followed by Bonferroni's test where appropriate. Spearman's correlation coefficients were used to examine the relationship between protein levels, plasma hormones and haemodynamic parameters. A value of P<0·05 was accepted as statistically significant.
Results
Haemodynamic and neurohumoral parameters
Haemodynamic and neurohumoral parameters are shown in Table 1 . Patients with end-stage heart failure demonstrated severe impairment of haemodynamics, as evaluated by right heart catheterization and echocardiography. Compared to healthy controls, all neurohumoral parameters were higher in heart failure. Moreover, Na + -Ca 2+ -exchanger protein levels were significantly increased by 56% and SR-Ca 2+ -ATPase protein levels were significantly decreased by 20% in end-stage failing hearts (Na + -Ca 2+ -exchanger: 97 6, n=23 failing and 62 13, n=9 non-failing myocardium, and SR-Ca 2+ -ATPase: 82 5, n=23 failing and 102 7, n=9 non-failing myocardium, Fig. 1 ).
Correlations between protein expression, plasma hormones and haemodynamics
As shown in Fig. 2 , there was a significant positive correlation between plasma norepinephrine levels and Na + -Ca 2+ -exchanger protein levels (r=0·64, P<0·01), while no correlation was found with SR-Ca 2+ -ATPase protein levels. There was a negative correlation between Na + -Ca 2+ -exchanger protein levels and fractional shortening (r= 0·56, P<0·05). No significant correlation was found between Na + -Ca 2+ -exchanger and SR-Ca 2+ -ATPase protein levels and other haemodynamic parameters or plasma levels of epinephrine, renin activity, atrial natriuretic peptide, aldosterone, TNF-, serum sTNF-R1 or sTNF-R2. In order to account for differences in connective tissue content, Na + -Ca 2+ -exchanger and SR-Ca 2+ -ATPase protein levels were normalized to calsequestrin. There was no significant correlation for calsequestrin with any other parameter.
Protein and hormonal levels and malignant ventricular arrhythmias
Figure 3 demonstrates differences in Na + -Ca 2+ -exchanger protein levels and plasma norepinephrine levels, when patients were divided into subgroups according to findings in Holter ECGs. Patients with sustained or non-sustained ventricular tachycardia (d3 consecutive beats) had significantly higher Na + -Ca 2+ -exchanger protein levels (+31%) and plasma norepinephrine levels (+107%) compared with patients presenting a maximum of two consecutive ventricular beats (Na + -Ca 2+ -exchanger: 109 10 vs 83 7; norepinephrine: 1359 159 vs 656 88 pg ml 1 ). Na + -Ca 2+ -exchanger protein levels in the 'high grade' arrhythmia group were significantly higher compared to healthy controls (62 13, n=9), whereas no significant differences were found for patients assigned to the 'low grade' arrhythmia group. No significant difference was found for other neurohumoral parameters or SR-Ca 2+ -ATPase protein level classes (89 9 vs 75 5, P>0·05) with respect to arrhythmia groups.
Discussion
The present study shows that (1) plasma norepinephrine correlates with myocardial Na + -Ca 2+ -exchanger, (2) increased expression of the Na + -Ca 2+ -exchanger is associated with increased occurrence of malignant ventricular arrhythmias.
In accordance with previous studies [1] [2] [3] [4] 7] , our data show an increase in Na + -Ca 2+ -exchanger protein levels of 56% and a decrease in SR-Ca 2+ -ATPase protein levels of 20% in end-stage failing myocardium, as compared with non-failing controls. However, the literature on the expression of Na + -Ca 2+ exchanger in heart failure is controversial [e.g. 5, 6] . We describe for the first time a relationship between plasma norepinephrine levels and myocardial Na + -Ca 2+ exchanger protein levels in human heart failure. This may partly explain the controversial reports on Na + -Ca 2+ exchanger expression in heart failure. Our data may indicate that plasma catecholamines are involved in gene regulation of the Na + -Ca 2+ exchanger. Further support for this hypothesis comes from recent studies performed in rat myocardium [12] [13] [14] . Golden and co-workers investigated the effect of catecholamine treatment of adult rats by means of an implanted osmotic minipump. Continuous 
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+ -Ca 2+ -exchanger in human heart failure 1121 application of the pure -adrenoceptor agonist isoproterenol, the relatively pure -adrenoceptor agonist phenylephrine, or norepinephrine which exerts its action through -and -adrenoceptor stimulation caused a 35-85% increase in Na + -Ca 2+ exchanger mRNA. Sevenday treatment with norepinephrine also stimulated a 35% increase in protein abundance [14] . Another study by the same group used a 4 h stimulation of neonatal cultured rat ventricular myocytes with 8-Br-cAMP, a synthetic cAMP analogue, and the PKC activator phorbol myristate acetate [13] in order to demonstrate the dependence of Na + -Ca 2+ exchanger regulation of transmembrane signalling via -and -adrenoceptors to activate protein kinase A and C, respectively.
Interestingly, the present study using human myocardium failed to demonstrate a significant correlation of plasma epinephrine with Na + -Ca 2+ exchanger. Both norepinephrine and epinephrine exert -and -adrenoceptor stimulation, but the effect of epinephrine on -adrenoceptors is modest compared to norepinephrine. Stimulation of myocardial 1 -adrenergic receptors has been shown to induce myocyte hypertrophy characterized by the reexpression of a fetal gene program [20] and the induction of peptide growth factors [21] . 1 -adrenergic receptors are of low density in the human heart; however, in contrast to 1 -adrenergic receptors, which are downregulated, 1 -adrenergic receptors appear to be unchanged in number in failing human myocardium [22] . Besides sympathetic activation, chronic heart failure is characterized by the activation of the renin-angiotensin system and increased levels of plasma cytokines. The role of these plasma markers in the course of heart failure has been elucidated, denoting a role in apoptosis and the induction of proapoptotic genes. Activation of the tumour necrosis factor system has been shown to correlate directly with fatal prognosis and the severity of heart failure [9, 10, 23, 24] . In the present study, end-stage heart failure was associated with significant activation of the renin-angiotensin and tumour necrosis factor systems as compared to healthy controls [16] . One could argue that the correlation between plasma norepinephrine and Na + -Ca 2+ -exchanger was artificial because of general neurohumoral activation in heart failure paralleled by and independent of upregulation of the Na + -Ca 2+ -exchanger. However, only plasma norepinephrine and not activation of the renin-angiotensin and tumour necrosis factor systems were significantly correlated with Na + -Ca 2+ -exchanger protein levels. Moreover, SR-Ca 2+ -ATPase protein levels were not significantly correlated with any neurohumoral parameter. Thus, the correlation of the Na + -Ca 2+ exchanger with norepinephrine seems special but can scarcely be explained only by the severity of heart failure. Of note, it must be mentioned that most patients were under treatment with ACE inhibitors. Thus, a potential role of the renin angiotensin system in the gene regulation of Ca 2+ cycling proteins may be masked. The functional implications of Na + -Ca 2+ -exchanger expression in failing myocardium are still controversial. We found a negative correlation between fractional shortening and the Na + -Ca 2+ -exchanger. This may indicate that patients with the most severely compromised left ventricular function have the highest myocardial Na + -Ca 2+ -exchanger protein levels. This is in contrast to a recent study from Piper et al. who found no differences in Na + -Ca 2+ -exchanger transcript levels at different stages of heart failure [6] . We further show that increased expression of the Na + -Ca 2+ exchanger was associated with increased incidence of malignant ventricular arrhythmias. Of course, this does not prove causability. We would nevertheless like to speculate on the underlying mechanisms. Ca 2+ elimination via Na + -Ca 2+ -exchange is electrogenic. Thus, an inward current is generated each time the Na + -Ca 2+ exchanger is working in its forward mode [15] . In hypertrophy and heart failure, cytoplasmic Ca 2+ overload can induce spontaneous SR Ca 2+ release followed by transient inward currents, which were blamed for provoking arrhythmogenic, delayed afterdepolarizations [reviewed in 25] . Induction of arrhythmias may also follow short episodes of either bradycardia or tachycardia, which are associated with increased calcium influx or SR Ca Table 2 . Protein levels were normalized to calsequestrin *P<0·05, #P<0·001.
exchanger activity. Increased expression and function of the Na + -Ca 2+ exchanger may therefore result in triggered arrhythmias and may be of high clinical relevance.
However, because patients with malignant arrhythmias also had high plasma norepinephrine levels that have been shown to correlate directly with fatal prognosis due to sudden cardiac death or progressive worsening of heart failure [26] it is not possible to differentiate which factor may be causal. Of note, recently in animal models of heart failure, increased exchanger activity was also associated with increased arrhythmias [27, 28] . Pogwizd and co-workers investigated the effect of combined aortic insufficiency and constriction in a rabbit heart failure model that was shown to be associated with ventricular arrhythmias initiated by a non-reentrant mechanism. In this model, about a twofold increase in the Na + -Ca 2+ exchanger at the protein and transcript level was reported. Induction of arrhythmias were ascribed to trigger activity from delayed afterdepolarizations, which were a result of about a twofold increase in the Na + -Ca 2+ exchanger current measured under controlled voltage clamp conditions [27] . Sipido and coworkers provide additional data from a canine model of heart failure with chronic complete atrioventricular block. This model is characterized by biventricular hypertrophy and ventricular arrhythmias. The study reported increased Ca 2+ influx by reverse-mode Na + -Ca 2+ exchange in isolated myocytes at low stimulation frequencies, which significantly contributes to SR-Ca 2+ load. This, however, may at the same time increase the propensity to cellular Ca 2+ overload and contribute to arrhythmogenesis during spontaneous SR Ca 2+ release [28] . Finally, as a consequence of the present data, consideration should be given as to whether inhibition of sympathetic activity aimed to prevent Na + -Ca 2+ exchanger over-expression or drugs capable of modulating Na + -Ca 2+ exchange would be an appropriate therapeutic strategy in heart failure. One must be cautious, however, since the available data from the literature, with respect to Na + -Ca 2+ exchanger expression and function in human heart failure as well as animal models are controversial, as discussed earlier. After all, from this and other studies the concept evolves that different genotypes and functional phenotypes dependent upon the underlying stimuli can be found in end-stage heart failure. Na + -Ca 2+ exchanger over-expression could be deleterious in some patients, as suggested in the present study, but could be beneficial in others [7] . We have to learn more about heterogeneity in end-stage heart failure in order to identify individuals who may profit from therapeutic interventions targeted to Na + -Ca 2+ exchange.
Limitations of the study
Only two out of 23 patients were under treatment with beta-blockers. The use of beta-blockers in end-stage heart failure is rapidly increasing. However, in the present study the number of patients presenting contraindications against beta-blocker treatment (e.g. symptomatic bradycardia or hypotension) was particularly high. The two patients on beta-blockers had low Na + -Ca 2+ exchanger and norepinephrine values and were assigned as 'low grade' arrhythmia patients (Na + -Ca 2+ exchanger: 85, norepinephrine: 800 pg ml 1 and Na + -Ca 2+ exchanger: 65 pg ml 1 , norepinephrine: 555, respectively).
